iFlow™ PLGA Microparticle Synthesis System
Drug (API) Microencapsulation
Microparticles, especially polymer microparticles, have shown great potential for biomedical applications in a variety of fields such as pharmaceutical industries like drug delivery, and biosensing because of its excellent properties.
PLGA microparticle synthesis by microfluidic technology presents advantages over the conventional batch synthesis processes due to its capacity in better uniformity in size and shape.
Principle of Particle Synthesis:
The iFlow system is widely used for PLGA microparticle synthesis and production. It employs microfluidic devices for controlled and tunable polymer microparticles production. The schematic below illustrates the device with junction in focused-flow geometry designed for microparticles’ synthesis.
Microparticle Synthesis:
Schematic illustration of enlarged junction, controlled break-up micro-droplet at the orifice. The flow through the orifice enables a controlled droplets break-up, which is required for yielding monodisperse microparticles
System Benefits:
High Performance & Efficiency
-
Tunable size
-
Low PDI
-
High encapsulation efficiency
Total Solution
-
Dedicated protocol
-
Technical support
-
Including everything you need
Cost Effective
-
Affordable configurations
-
Cost effective solutions
-
Open platform
Custom Design & Service
-
Research collaboration
-
Custom design
-
OEM & Contract manufacturing
Advantages of Microfluidic Method:
The iFlow system offers a variety of numerous benefits by using microfluidic systems to produce PLGA mircoparticles for drug delivery applications, such as:
-
Enhanced control of particle fabrication process over each phase
-
High yields
-
Easy scale-up
In drug delivery, precise particle production is essential for controlled and sustained release of drugs using biodegradable polymers. The iFlow systems offer advantages like enhanced control over particle production, higher yields, and easy scale-up. Targeted drug delivery is also possible by functionalizing particle surfaces or using the EPR effect. The release profiles of the polymer-drug matrix can be adjusted by varying factors like microparticle size, polymer molecular weight, lactide to glycolide ratio, and drug concentration.
Related Applications Notes:
PLGA Droplet-based Microparticle Synthesis
PLGA Microparticles are produced via template droplets that turn into microparticles by solvent evaporation. Easy to generate PLGA droplets.
